Organova Terminates Tarveda Merger
So, let’s back up a bit with this one – back to 2019 when things were much simpler. Organova, a company that specializes in 3-D Bioprinted tissues, reset after it failed to generate decisive scientific data to support the prolonged functionality and therapeutic benefit of its liver tissue candidate. The company was exploring strategic options that would include the potential for an acquisition, merger, reverse merger, business combination, sale of assets, licensing, or other strategic transactions.
Then along came Tarveda Therapeutics, which Organova wanted to acquire in an all-stock transaction. The Watertown, MA-based company was very attractive and would give Organova an entry into the precision oncology medicines. However, Organova terminated the merger agreement in April at the height of COVID-19 concerns in the U.S.